RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Arch Therapeutics Stock

Arch Therapeutics P/S 2024

Arch Therapeutics P/S

0.02

Ticker

ARTH

ISIN

US03939W1099

WKN

A1W2JT

As of Nov 17, 2024, Arch Therapeutics's P/S ratio stood at 0.02, a -99.98% change from the 121.8 P/S ratio recorded in the previous year.

The Arch Therapeutics P/S history

Arch Therapeutics Aktienanalyse

What does Arch Therapeutics do?

Arch Therapeutics Inc. is a Massachusetts-based company specializing in the development of medical devices. The company was founded in 2006 and has expanded its activities to manufacturing innovative medical products that can be used in various surgical procedures. The business model of Arch Therapeutics is based on the development of medical devices that aim to enable faster recovery for patients. The company utilizes a patented technology platform called "AC5" for the manufacturing and marketing of devices for various medical applications. The company has various divisions specializing in different medical applications. One main focus is the development of devices for hemostasis (blood clotting) in surgery, which is currently in the testing phase. Arch Therapeutics aims to provide a better alternative to existing solutions such as surgical clips or sutures, which are often associated with undesirable side effects. Another focus of Arch Therapeutics is the manufacturing of devices for dermatology. The company has developed a technology that enables a new and unique process for the rapid healing of wounds. This process is especially relevant for the treatment of difficult-to-heal wounds and chronic wounds. The company also has a division for ophthalmic surgery, which has developed a patented device technology for the treatment of glaucoma-related issues. This technology is intended to be a better alternative to conventional treatment methods such as eye drops. Arch Therapeutics' portfolio includes a wide range of medical devices and solutions for various medical applications. These products are designed to enable better patient recovery and have been developed by a group of experts, ensuring high quality and effectiveness. The offered products also include dermatology products, adhesion barriers, surgical J-clips, as well as wound closure and hemostasis devices. Overall, Arch Therapeutics has a strong potential for growth and expansion in the medical device industry. The company has already obtained patents for its AC5 platform and developed a wide range of products for various medical applications. With a dedicated team of employees, the company has laid a strong foundation for its future and is expected to remain a leading provider of medical devices in the coming years. Arch Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Arch Therapeutics's P/S Ratio

Arch Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Arch Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Arch Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Arch Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Arch Therapeutics stock

What is the price-to-earnings ratio of Arch Therapeutics?

The price-earnings ratio of Arch Therapeutics is currently 0.02.

How has the price-earnings ratio of Arch Therapeutics changed compared to last year?

The price-to-earnings ratio of Arch Therapeutics has increased by -99.98% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Arch Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Arch Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Arch Therapeutics affect the company?

An increase in the price-earnings ratio of Arch Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Arch Therapeutics affect the company?

A decrease in the price-earnings ratio of Arch Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Arch Therapeutics?

Some factors that influence the price-earnings ratio of Arch Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Arch Therapeutics pay?

Over the past 12 months, Arch Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arch Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Arch Therapeutics?

The current dividend yield of Arch Therapeutics is .

When does Arch Therapeutics pay dividends?

Arch Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arch Therapeutics?

Arch Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Arch Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arch Therapeutics located?

Arch Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arch Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arch Therapeutics from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Arch Therapeutics pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Arch Therapeutics in the year 2023?

In the year 2023, Arch Therapeutics distributed 0 USD as dividends.

In which currency does Arch Therapeutics pay out the dividend?

The dividends of Arch Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Arch Therapeutics

Our stock analysis for Arch Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arch Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.